Armata Pharmaceuticals, Inc. (ARMP) - Form 8-K Summary
Business Context and Reporting Period
Armata Pharmaceuticals, Inc. filed this Current Report on Form 8-K on March 25, 2026. The filing serves to announce the company's financial results for the three months and the full fiscal year ended December 31, 2025. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 25, 2026) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate based on the full-year 2025 results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if there were any changes in capital structure or financing activities during the reported period.